Navigation Links
Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
Date:12/1/2008

rtunity for PBI, and we expect to take full advantage of the growing acceptance of the PCT Sample Preparation System in the mass spectrometry market going forward."

Mr. Schumacher continued: "Despite the current, difficult economic environment, we reported record installations and revenue for the third quarter of 2008, and have continued to observe strong interest for PCT-related products during the current fourth quarter. We believe this is confirmation that market acceptance of the PCT Sample Preparation System has begun. We have approximately 20 NEP3229 instruments in inventory, and have ordered an additional 50 NEP2320 instruments for receipt during the next three months. These instruments are very important to our future growth and revenue expectations."

Mr. Schumacher concluded: "We have reduced our cash burn and extended our cash resources through the second quarter of 2009, we have maintained our key staff, we have sharpened our focus to the mass spectrometry market where we have significant competitive advantages, we have refocused our sales efforts to specific PCT product areas where market penetration and customer purchases have begun, we have active evaluations being performed with key thought leaders and with potential customers and strategic partners, and we are optimistic that we will successfully complete our current equity financing. We firmly believe that market acceptance of PCT has begun, that it is important to extend our cash resources to give us more time to take advantage of developing opportunities, that a new, sharpened focus is crucial to our growth and development, and that we are now prepared for success going forward."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrost
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Specific antagonism lowers blood pressure
3. Doctors Often Miss High Blood Pressure in Kids
4. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
5. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
6. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
7. AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
8. Memory tasks require more coordinated brain blood flow for people with high blood pressure
9. Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids Licensed Foods and Beverages
10. High Blood Pressure & Stroke Attack was the Focus for the Third Stop of the 2007 Empowerment Tour for a Healthier Life
11. Daytime, Nighttime Blood Pressure Both Important
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The North America Endpoint Security Market ... in North America with analysis and forecast of revenue. ... billion in 2014 to $4.77 billion by 2019, at ... Browse through the TOC of the North America Endpoint ... in-depth analysis provided. It also provides a glimpse of ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... NY) Scientists at Albert Einstein College of ... that aid in digestion help keep the intestinal lining ... Immunity , could yield new therapies for inflammatory bowel ... , The research involved the intestinal microbiome, which contains ... in promoting or preventing disease is a major emerging ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... Birth control pills containing high doses of estrogen, along ... breast cancer in women under 50, new preliminary ... explained lead researcher Elisabeth Beaber, a staff scientist at ... of these formulations increase breast cancer risk while other ...
Breaking Medicine News(10 mins):Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Mass., Oct. 13 Boston Scientific Corporation (NYSE: ... launch of its Journey™ Guidewire, an innovative 0.014" ... peripheral angioplasty procedures.  The Journey Guidewire strengthens Boston ... physician needs in treating arteries below the knee. ...
... SKILLMAN, N.J., Oct. 13 ConvaTec, a world-leading developer ... hospital care, today announced that its top executives have ... MedTech Conference , the premier medical technology conference for ... from around the world. Well known ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Journey™ Guidewire 2Boston Scientific Announces Global Launch of Journey™ Guidewire 3ConvaTec to Present at AdvaMed 2010: The MedTech Conference 2
... Fat Harvest, Wash & Transfer System is ... make fat transfer procedures simpler for the ... the need for an office-based technique. LipiVage™ ... is no longer a need to centrifuge, ...
... Type B) Injectable Solution, the only Botulinum ... demonstrated in numerous published studies to be ... Delivered as a purified, ready-to-use solution, ... a simpler way to significantly reduce abnormal ...
... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...
Inquire...
Medicine Products: